# First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

> **NCT00607906** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 36 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** SB-756050 immediate release capsule
- **DRUG:** SB-756050 modified release capsule
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00607906
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11-16
- **Primary completion:** 2008-03-10
- **Final completion:** 2008-03-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00607906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00607906, "First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00607906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*